Castellano | Euskara | Français | English
DAR No 4: Naloxegol. Moventig® for opioid-induced constipation
Share it
No data available on the target population
- The most common adverse reaction include dose-related gastrointestinal disorders. Although its safety profile is considered acceptable and no warning signs have been observed in terms of cardiovascular safety, a slight increase of blood pressure and syncope has been observed.
- Observational post-marketing studies should be performed to determine its potential cardiovascular risk, and safety profile in patients with cancer.
- Its efficacy has only been proven in patients with constipation caused by opioids for non-cancer pain. No data are available on patients with cancer-related pain.
- The cost per patient is higher compared to other rescue laxatives.
